Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.

Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke MA, March JS.

J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):711-20. doi: 10.1097/CHI.0b013e3181a2b319.

PMID:
19465880
2.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

3.

The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.

March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J.

Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101.

PMID:
17909125
4.

Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.

Revicki DA, Siddique J, Frank L, Chung JY, Green BL, Krupnick J, Prasad M, Miranda J.

Arch Gen Psychiatry. 2005 Aug;62(8):868-75.

PMID:
16061764
5.

Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.

Sava FA, Yates BT, Lupu V, Szentagotai A, David D.

J Clin Psychol. 2009 Jan;65(1):36-52. doi: 10.1002/jclp.20550.

PMID:
19051275
6.

Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.

Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS.

J Ment Health Policy Econ. 2010 Mar;13(1):27-35.

PMID:
20571180
7.

Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).

Lewis CC, Simons AD, Nguyen LJ, Murakami JL, Reid MW, Silva SG, March JS.

J Am Acad Child Adolesc Psychiatry. 2010 Feb;49(2):132-40.

PMID:
20215935
8.

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.

Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, Chatwin J, Goddard J, Thornett A, Smith H, Campbell M, Thompson C.

Health Technol Assess. 2005 May;9(16):1-134, iii.

9.

Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial.

Sacristán JA, Gilaberte I, Boto B, Buesching DP, Obenchain RL, Demitrack M, Pérez Sola V, Alvarez E, Artigas F.

Int Clin Psychopharmacol. 2000 Mar;15(2):107-13.

PMID:
10759342
10.

Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression.

Byford S, Barrett B, Roberts C, Wilkinson P, Dubicka B, Kelvin RG, White L, Ford C, Breen S, Goodyer I.

Br J Psychiatry. 2007 Dec;191:521-7.

PMID:
18055956
11.

Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.

Serrano-Blanco A, Gabarron E, Garcia-Bayo I, Soler-Vila M, Caramés E, Peñarrubia-Maria MT, Pinto-Meza A, Haro JM; Depressió en Atenció Primària de Gavà Group (D. A. P. G. A.).

J Affect Disord. 2006 Apr;91(2-3):153-63. Epub 2006 Feb 3.

PMID:
16458976
12.

Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.

Perlis RH, Nierenberg AA, Alpert JE, Pava J, Matthews JD, Buchin J, Sickinger AH, Fava M.

J Clin Psychopharmacol. 2002 Oct;22(5):474-80.

PMID:
12352270
13.

Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.

Russell JM, Berndt ER, Miceli R, Colucci S, Grudzinski AN.

Am J Manag Care. 1999 May;5(5):597-606.

14.
15.

The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.

March J, Silva S, Vitiello B; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1393-403.

PMID:
17135984
16.
17.

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.

Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC, Panish JM.

J Clin Psychopharmacol. 2004 Oct;24(5):497-506.

PMID:
15349005
18.

Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).

Curry J, Rohde P, Simons A, Silva S, Vitiello B, Kratochvil C, Reinecke M, Feeny N, Wells K, Pathak S, Weller E, Rosenberg D, Kennard B, Robins M, Ginsburg G, March J; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1427-39.

PMID:
17135988
19.

The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis.

McLoughlin DM, Mogg A, Eranti S, Pluck G, Purvis R, Edwards D, Landau S, Brown R, Rabe-Heskith S, Howard R, Philpot M, Rothwell J, Romeo R, Knapp M.

Health Technol Assess. 2007 Jul;11(24):1-54.

20.

Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?

Serrano-Blanco A, Suárez D, Pinto-Meza A, Peñarrubia MT, Haro JM; DAPGA Group (Depressió en Atenció Primària de Gavà).

J Eval Clin Pract. 2009 Feb;15(1):195-203. doi: 10.1111/j.1365-2753.2008.00982.x.

PMID:
19239602

Supplemental Content

Support Center